Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-N531 in Duchenne Muscular Dystrophy (OLE)
NCT07209332Phase 2Enrolling by invitation
- Sponsor
- Wave Life Sciences
- Start
- Dec 2025
- Primary completion
- Mar 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of WVE-N531 in Duchenne muscular dystrophy (DMD), sponsored by Wave Life Sciences. Started Dec 2025; status: enrolling by invitation.
02
Drugs
WVE-N531
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07209332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209332.